Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Trade receivables and contract assets

v3.25.4
Trade receivables and contract assets
12 Months Ended
Dec. 31, 2025
Trade Receivables And Contract Assets [Abstract]  
Trade receivables and contract assets

21. Trade receivables and contract assets

Trade receivables and contract assets are analyzed as follows:

 

 

 

At December 31,

 

 

At December 31,

 

 

 

2025

 

 

2024

 

 

 

(EUR thousand)

 

Trade receivables

 

 

309,772

 

 

 

302,655

 

Allowance for expected credit losses

 

 

(7,084

)

 

 

(6,704

)

Total trade receivables

 

 

302,688

 

 

 

295,951

 

 

 

 

 

 

 

 

 

Trade receivables are non-interest bearing and credit terms are generally 60 to 90 days. The Group is not exposed to significant concentration of third-party credit risk.

Trade receivables breakdown by geographical area is shown below:

 

 

 

At December 31,

 

 

At December 31,

 

 

 

2025

 

 

2024

 

 

 

(EUR thousand)

 

EMEA

 

 

159,156

 

 

 

147,675

 

APAC

 

 

35,828

 

 

 

43,989

 

North America

 

 

101,615

 

 

 

101,416

 

South America

 

 

13,173

 

 

 

9,575

 

Total Trade Receivables

 

 

309,772

 

 

 

302,655

 

Trade receivables are stated net of an allowance for expected credit losses which has been determined in accordance with IFRS 9 amounting to EUR 7,084 thousand and EUR 6,704 thousand for 2025 and 2024 respectively:

 

 

 

2025

 

 

2024

 

 

 

(EUR thousand)

 

At January 1

 

 

6,704

 

 

 

6,656

 

Accruals

 

 

1,134

 

 

 

1,411

 

Releases

 

 

(469

)

 

 

(1,346

)

Utilizations

 

 

(36

)

 

 

(25

)

Exchange differences and other changes

 

 

(249

)

 

 

8

 

At December 31

 

 

7,084

 

 

 

6,704

 

 

Contract assets

Contract assets relate to ongoing customer-specific construction contracts within the Engineering segment, as well as to activities from the In-vitro diagnostic and DDS businesses, both of which are included in the Biopharmaceutical and Diagnostic Solutions segment. As such, the balance of this account fluctuates depending on the number and stage of construction contracts in progress at each reporting date. The Group recognized contract assets of EUR 180,459 thousand at December 31, 2025 and of EUR 168,515 thousand at December 31, 2024. On a gross basis, contract assets amounted to EUR 478,694 thousand (EUR 414,955 thousand at December 31, 2024), net of advance invoices issued of EUR 298,235 thousand (EUR 246,440 thousand at December 31, 2024).